FDA (CDER)
GUIDANCE FINAL
Clostridioides difficile Infection: Developing Drugs for Treatment, Reduction of Recurrence, and Prevention
Published: 5/8/2026Detected: 5/8/2026
Summary preview
Clarifies FDA expectations for developing drugs intended to treat, reduce recurrence of, and prevent Clostridioides difficile infection (CDI), emphasizing scientifically grounded clinical and safety evidence.
Get the full analysis, free
Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.
Create free accountinfectious_disease
clinical
safety
labeling
clinical
#Clostridioides difficile
#CDI
#treatment
#recurrence
#prevention
Official Source Document Source Verified
Access the original document directly from FDA CDER.
More from FDA (CDER)
- E14 and S7B Clinical and Nonclinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential--Questions and Answers (R1): Guidance for Industry10/30/2026
- Submitting Clinical Trial Data to Evaluate the Ability to Operate a Motor Vehicle10/20/2026
- Regulatory Considerations for Prescription Drug Use-Related Software10/20/2026
- Safety Reporting Requirements for INDs and BA/BE Studies: Guidance for Industry and Investigators10/19/2026
- Postapproval Manufacturing Changes to Biosimilar and Interchangeable Biosimilar Products: Questions and Answers10/9/2026